Eldecalcitol
drugOn this page
Also known as Ed-71
Summary
Eldecalcitol (CHEMBL4297608) is a phase-3 clinical-stage small molecule targeting VDR; indicated across 1 condition including osteoporosis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (VDR)
- Indications: 1 condition
- Clinical trials: 7
- Chemistry: 490.7 Da · C30H50O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297608 |
| Name | Eldecalcitol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 6918141 |
| ChEBI | CHEBI:73927 |
| Molecular formula | C30H50O5 |
| Molecular weight | 490.7 |
| InChIKey | FZEXGDDBXLBRTD-AYIMTCTASA-N |
SMILES: C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H]([C@H]([C@@H](C3=C)O)OCCCO)O)C
IUPAC name: (1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
ChEBI definition: A hydroxycalciol that is calcitriol with a 3-hydroxypropoxy group at position 2.
Other ChEBI roles (chemical / environmental): metabolite.
Also known as: Ed-71, Eldecalcitol, ELDECALCITOL
Patent coverage: 106 distinct patent families (197 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| VDR | Vitamin D receptor | Agonist | 8 | 0.2% | P11473 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): VDR.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Vitamin D (calciferol) metabolism | 1 | VDR |
| Nuclear Receptor transcription pathway | 1 | VDR |
| SUMOylation of intracellular receptors | 1 | VDR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| cell morphogenesis | 1 |
| skeletal system development | 1 |
| calcium ion transport | 1 |
| intracellular calcium ion homeostasis | 1 |
| lactation | 1 |
| negative regulation of cell population proliferation | 1 |
| positive regulation of gene expression | 1 |
| negative regulation of keratinocyte proliferation | 1 |
| cell differentiation | 1 |
| positive regulation of bone mineralization | 1 |
| intracellular receptor signaling pathway | 1 |
| phosphate ion transmembrane transport | 1 |
| nuclear receptor-mediated bile acid signaling pathway | 1 |
| mRNA transcription by RNA polymerase II | 1 |
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| osteoporosis | 3 | MONDO:0005298 | EFO:0003882 |
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05902078 | PHASE4 | RECRUITING | Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis |
| NCT06537115 | PHASE4 | RECRUITING | Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia |
| NCT05884372 | PHASE4 | COMPLETED | Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT) |
| NCT06385093 | PHASE4 | UNKNOWN | A Study on the Prevention and Treatment of GIOP With Eldecalcitol |
| NCT00144456 | PHASE3 | COMPLETED | A New Active Vitamin D, ED-71 for Osteoporosis |
| NCT01974167 | Not specified | UNKNOWN | Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol |
| NCT05433207 | Not specified | UNKNOWN | Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
10 molecules share ≥1 primary target. Top 10 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CALCIPOTRIENE | ChEMBL | Phase 4 (approved) | VDR |
| CALCITRIOL | ChEMBL | Phase 4 (approved) | VDR |
| CHOLECALCIFEROL | ChEMBL | Phase 4 (approved) | VDR |
| DOXERCALCIFEROL | ChEMBL | Phase 4 (approved) | VDR |
| TACALCITOL | ChEMBL | Phase 4 (approved) | VDR |
| CURCUMIN | ChEMBL | Phase 3 | VDR |
| MAXACALCITOL | ChEMBL | Phase 3 | VDR |
| SEOCALCITOL | ChEMBL | Phase 3 | VDR |
| TAUROLITHOCHOLIC ACID | ChEMBL | Phase 3 | VDR |
| chenodiol | PubChem | Approved | VDR |
Related Atlas pages
- Genes: VDR
- Diseases: osteoporosis
- Drugs: Calcipotriene, Calcitriol, Cholecalciferol, Doxercalciferol, Tacalcitol, Curcumin, Maxacalcitol, Seocalcitol, Taurolithocholic Acid, chenodiol